Published in Neuropharmacology on December 20, 2016
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology (2017) 0.78
Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods (1994) 23.05
Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods (2009) 18.51
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain (1988) 18.17
Ethical guidelines for investigations of experimental pain in conscious animals. Pain (1983) 17.70
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
The formalin test: an evaluation of the method. Pain (1992) 7.29
Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol (1980) 6.82
Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain (2000) 6.21
Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol (2015) 5.43
Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther (1997) 5.20
Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem (1995) 4.53
Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol (2015) 4.46
Characterization of a rat model of incisional pain. Pain (1996) 3.55
State-dependent opioid control of pain. Nat Rev Neurosci (2004) 3.51
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther (2006) 2.82
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 1.76
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience (2005) 1.76
Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther (2007) 1.66
"Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev (2007) 1.62
Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain (2006) 1.61
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett (2013) 1.45
Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci (2004) 1.40
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics (2009) 1.36
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2008) 1.28
In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol (2007) 1.20
Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol (2011) 1.20
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Overview of brain microdialysis. Curr Protoc Neurosci (2009) 1.05
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci (2010) 1.04
Histological studies of the effects of chronic implantation of ceramic-based microelectrode arrays and microdialysis probes in rat prefrontal cortex. Brain Res (2009) 1.03
1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol Dis (2009) 1.03
Separation of morphine analgesia from physical dependence. Science (1984) 1.00
The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology (2010) 0.99
Non-medical use of prescription opioids during the transition to adulthood: a multi-cohort national longitudinal study. Addiction (2013) 0.96
Microglia disrupt mesolimbic reward circuitry in chronic pain. J Neurosci (2015) 0.93
The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology (Berl) (2013) 0.93
Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.92
Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther (1988) 0.90
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res (2013) 0.89
Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuropsychopharmacology (2013) 0.87
FDA asks physicians to stop prescribing high-dose acetaminophen products. JAMA (2014) 0.87
Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol (2012) 0.86
Action of kappa and Delta opioid agonists on premotor cardiac vagal neurons in the nucleus ambiguus. Neuroscience (2004) 0.84
The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol (2014) 0.84
Nonmedical use of prescription opioids among adolescents: subtypes based on motivation for use. J Addict Dis (2012) 0.83
Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol. Addict Biol (2013) 0.83
Cardiovascular changes during morphine administration and spontaneous withdrawal in the rat. Eur J Pharmacol (1999) 0.83
A unique modulator of endoplasmic reticulum stress-signalling pathways: the novel pharmacological properties of amiloride in glial cells. Br J Pharmacol (2009) 0.83
Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice. J Pharmacol Exp Ther (2015) 0.83
Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci Lett (2014) 0.82
Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience (2015) 0.82
Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther (2013) 0.82
Safety concerns with long-term opioid use. Expert Opin Drug Saf (2016) 0.78
Cannabinoids for neuropathic pain. Curr Pain Headache Rep (2014) 0.77
Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use. J Stud Alcohol Drugs (2015) 0.76
Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain. J Med Chem (2016) 0.76
The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief. ISRN Anesthesiol (2011) 0.76